NanoViricides Reports Promising Results for NV-387 in Treating Influenza A

NanoViricides, Inc. has announced significant findings regarding its drug candidate NV-387's effectiveness against the Influenza A virus, including potential activity against the H5N1 Bird Flu virus. In comparison trials involving approved anti-influenza drugs, NV-387 demonstrated a superior ability to extend survival in a lethal mouse model of lung infection caused by the H3N2 virus.

In a detailed study, mice infected with the Influenza A/H3N2 virus were treated with NV-387, experiencing a median survival of 15 days. This contrasts with survival spans of 10, 11, and 11 days for those treated with Oseltamivir, Peramivir, and Baloxivir, respectively. Notably, NV-387's performance indicates a significant improvement in survival rates compared to these established drugs.

The company emphasizes NV-387's broad-spectrum antiviral potential, suggesting that the structural properties of the H5N1 virus could make it particularly susceptible to NV-387. Despite these promising results, further research is required to confirm the drug's efficacy against a wider range of Influenza A viruses.

NanoViricides' President Anil R. Diwan expressed optimism about NV-387, highlighting its potential as a singular treatment option for multiple respiratory viruses, including H5N1, other forms of Influenza A, RSV, and Coronaviruses. The development of such a broad-spectrum antiviral could represent a revolution in antiviral therapy, particularly by reducing the potential for viral resistance through mutation.